References
Cantalamessa F, De Caro G, Massi M, Micossi LG. Ketanserin, a new selective 5-HT2 receptor blocking agent, inhibits the antidiuretic effect of 5-hydroxytryptamine (5-HT) in Wistar rats. Archives Internationales de Pharmacodynamie 162: 302–307, 1983
Dustan HP. Causes of inadequate response to antihypertensive drugs. Volume factors. Hypertension 5(Suppl. III): III–26–III–30, 1983
Erspamer V. Peripheral physiological and pharmacological actions of indolealkylamines. In Erspamer V (Ed.) Handbook of experimental pharmacology: 5-hydroxytryptamine and related indolealkylamines, vol. 19, pp. 245–359, Springer Verlag, Berlin, 1966
Fagard R, Cattaert A, Lijnen P, Staessen J, Vanhees L, et al. Responses of the systemic circulation and of the renin-angiotensin-aldosterone system to ketanserin at rest and exercise in normal man. Clinical Science 66: 17–25, 1984
Minami M, Yasuda H, Yamazaki N, Kojima S, Nishijima H, et al. Plasma norepinephrine concentration and plasma dopamine-beta-hydroxylase activity in patients with congestive heart failure. Circulation 67: 1324–1329, 1983
Minami M, Togashi H, Sano M, Yoshioka M, Saito I, et al. Effects of a new antihypertensive agent, 2-[4-(n-butyryl)-homo-piperazine-1-ul]-4-amino-6, 7-dimethoxy-quinazoline (E-643), on blood pressure, urinary sodium excretion and urinary norepinephrine excretion rate in stroke-prone spontaneously hypertensive rats (in Japanese). Hokkaido Journal of Medical Science 60: 536–543, 1985
Mulvihil-Wilson J, Graham RM, Pettinger WA, Mucklerog C, Anderson S, et al. Comparative effects of prazosin and phenoxybenzamine on arterial blood pressure, heart rate and plasma catecholamine in essential hypertension. Journal of Cardiovascular Pharmacology 1 (Suppl.): 1–7, 1979
Okamoto K, Yamori Y, Nagaoka A. Establishment of the strokeprone SHR. Circulation Research 34(Suppl. 1): 143–153, 1974
Rahman MK, Nagatsu T, Kato T. Aromatic L-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with L-dopa and L-5-hydroxytryptophan as substrates. Biochemical Pharmacology 30: 645–649, 1981
Reimann IW, Frölich JC. Is ketanserin a D receptor antagonist? Lancet 1: 703–704, 1983
Sano M, Minami M, Togashi H, Yoshioka M, Tochihara M, et al. Effect of ketanserin on blood pressure in rats (in Japanese). Folia Pharmacologics Japonica 86: 401–409, 1985
Senjo M, Yamazaki N, Minami M, Hirokami M, Saito H, et al. Decreased monoamine oxidase activity in stroke-prone spontaneously hypertensive rat kidney. Research Communications in Chemical Pathology and Pharmacology 52: 207–216, 1986
Van Nueten JM, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren TJ, et al. Vascular effects of ketanserin (R41 468), a novel antagonist of 5-HT2 serotonergic receptors. Journal of Pharmacology and Experimental Therapeutics 218: 217–230, 1981
Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circulation Research 47: 1–9, 1980
Yoshioka M, Matsumoto M, Togashi H, Minami M, Saito H. Central sympathoinhibitory action of ketanserin in rats. Journal of Pharmacology and Experimental Therapeutics 243: 1174–1178, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Minami, M., Hamaue, N., Togashi, H. et al. Effects of Long Term Oral Administration of Ketanserin and Trichlormethiazide on Blood Pressure in Stroke-Prone Spontaneously Hypertensive Rats. Drugs 36 (Suppl 1), 92–96 (1988). https://doi.org/10.2165/00003495-198800361-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198800361-00016